SNGX

Soligenix, Inc. SNGX

SNGX
Soligenix, Inc. ENSC
Ensysce Biosciences, Inc. OGEN
Oragenics, Inc. CANF
Can-Fite BioPharma Ltd. QLGN
Qualigen Therapeutics, Inc. KZIA
Kazia Therapeutics Limited XBIO
Xenetic Biosciences, Inc. SILO
Silo Pharma, Inc. TTNP
Titan Pharmaceuticals, Inc. VYNE
VYNE Therapeutics Inc.

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode SNGX ENSC OGEN CANF QLGN KZIA XBIO SILO TTNP VYNE
6M -18.82 % -42.57 % -75.95 % -76.22 % -14.17 % 18.80 % -22.66 % -36.42 % -45.07 % -34.15 %
YTD -53.06 % -85.94 % -91.87 % -85.92 % -23.57 % 24.23 % -46.91 % -60.05 % -26.65 % -82.40 %
1Y -55.19 % -85.41 % -92.22 % -82.49 % -17.69 % -28.25 % -49.77 % -54.55 % -27.55 % -75.48 %
3Y -99.12 % -99.28 % -99.70 % -96.18 % -95.06 % -58.11 % -23.21 % -86.10 % -86.55 % -80.27 %
5Y -99.79 % -100.00 % -99.89 % -98.62 % -99.81 % -97.58 % -88.06 % 8.43 % -96.43 % -99.56 %
10Y -99.96 % -100.00 % -100.00 % -99.95 % -100.00 % -97.62 % -99.65 % 8.43 % -99.99 % -99.97 %
From the beginning -100.00 % -100.00 % -100.00 % -99.97 % -100.00 % -99.59 % -99.65 % 8.43 % -100.00 % -99.97 %

Dividend